PT  - JOURNAL ARTICLE
AU  - Dante J. Bellai
AU  - Mark G. Rae
TI  - A Systematic Review of the Association between the Age of Onset of Spinal-Bulbar Muscular Atrophy (Kennedy’s Disease) and the Length of CAG Repeats in the Androgen Receptor Gene
AID  - 10.1101/2023.02.08.23285647
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.08.23285647
4099  - http://medrxiv.org/content/early/2023/02/09/2023.02.08.23285647.short
4100  - http://medrxiv.org/content/early/2023/02/09/2023.02.08.23285647.full
AB  - Background Spinal bulbar muscular atrophy (SBMA) is an X-linked recessive motor neuron disorder which is caused by the presence of ≥ 38 CAG repeats in the androgen receptor gene. Relatively little is known about SBMA, but existing literature indicates a relationship between CAG repeat number and the onset age of some motor symptoms of SBMA. This literature review explored the effect of larger CAG repeats on the age of weakness onset compared to shorter length CAG repeats in male SBMA patients.Methods Three databases were searched (MEDLINE, SCOPUS, and Web of Science; Oct 2021) along with targeted searches in Cambridge University Press and Annals of Neurology. 514 articles were initially identified, of which 13 were included for qualitative synthesis.Results Eleven of the thirteen articles identified a statistically significant inverse correlation between CAG repeat length and age of weakness onset in SBMA. Five studies indicated that SBMA patients with fewer CAG repeats (e.g. 35-37) had an older age of weakness onset than patients with a greater number (e.g. >40) of CAG repeats. The minimum number of CAG repeats associated with weakness was numbered in the mid-to-late thirties.Conclusion Identification of a relationship between CAG repeat number and weakness may enable earlier detection and intervention for SBMA.Limitations of this review include the restriction to English-only studies and differences in statistical methodology used in each study. We recommend that future studies use interviews, chart reviews, and standardized scoring methods to reduce effects of retrospective bias on reporting SBMA signs and symptoms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors